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Abstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) is known as a primary indicator of acute and
chronic renal and can be effective in chronic kidney injury (CKI) with kidney tumors cisplatin (CP) chemotherapy.
The aim of this study was to evaluate serum and urinary biomarker including NGAL (sNGAL and uNGAL) in canine
with solid renal tumors who suffered from cisplatin after short and long-term chemotherapy.
Methods: In this study, in treatment and control groups, canine (n = 10 and n = 5) were administered cisplatin at
1.2 mg/kg/day (i.v.) for five consecutive days with CKI and without CKI, respectively. Serum and urine NGAL levels
(ng/mL) were evaluated at 0, 1, 5, 9, 13, 17, 21, 25 and 29 days after drug injection versus baseline in treated and
control groups.
Results: Canine in treatment group had shown symptoms of toxicity of cisplatin. The results indicated the higher
concentrations of serum, sNGAL and uNGAL (P = 0.024; P = 0.011) compared with control group (P = 0.701,
P = 0.612), (Table 2, Figs. 1 and 2). Indeed, our results showed that canine with CKI were associated with higher
levels of sNGAL and uNGAL compared with control group without CKI. Moreover, the highest level of uNGAL was
seen in comparison with sNGAL, after a high dose (1.2 mg/kg) administration of CP.
Conclusion: Our data suggested that U-NGAL may be useful for monitoring of renal injury in CKI patients that
exposed with cisplatin. Furthermore, a primary elevate in urinary NGAL expulsion may help in identifying cases at
danger of cisplatin-induced CKI that might profit from innovative remedies to prevent cisplatin nephrotoxicity.
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Background
Cisplatin (CP) found in the 1960s to inhibit cell division, is
currently one of the most widely used anticancer chemo-
therapy drugs [1, 2]. CP is mainly used for different kind
of cancer including head and neck cancer, esophageal can-
cer, genital cancer (i.e., testicular and ovarian cancer), cer-
vical cancer, and non-small-cell lung cancer [3, 4], and its
adverse clinical effects, including neurotoxicity, ototoxicity,
nephrotoxicity, nausea, and vomiting, remain challenging
for clinicians [1–3]. Clinically, CP-induced AKI occurs
about 10 days after CP treatment, and it is marked by a de-
cline in glomerular filtration rates, increased serum cre-
atinine levels, hypomagnesaemia, and hypokalemia [2, 4, 5].
Due to the high blood flow through the renal relative to
its mass and subsequent exposure to concentrated urine
including omitted xenobiotics the renal is one of the
known main signal tissues for medication-induced injury
[6]. Although clinicians have exerted efforts to prevent
CP-induced AKI, the results are not satisfactory. A bio-
marker that predicts AKI earlier than serum creatinine
levels may provide clinicians with more time to apply the
appropriate intervention [6, 7].
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Recent studies have investigated some biomarkers, in-
cluding NGAL, which is a 25-kDa protein. This biomarker
is known as an primary indicator of acute and chronic renal
trauma [7–14]. Low concentration of NGAL is present in
most human tissues but spikes when kidney, liver, colon,
and lung epithelial cells are damaged. Recently, there are a
number of studies that suggested serum and urine NGAL
are sensitive and specific biomarkers for the prediction of
AKI as well as the development of AKI among human pa-
tients after cardiac surgery [15], non-cardiac surgery [16],
and renal transplantation. It has been reported that the
expressions of NGAL are rapidly up-regulated after renal
injury and is highly expressed during ischemic renal injury
in animal models. It is worth noting that researches on
animal model have shown, which NGAL levels increase
after ischemic kidney injury or exposure to nephrotoxic
drugs [17–21].
In veterinary medicine, NGAL is a newly studied and
promising biomarker that has been shown to increase in
dogs with both AKI and chronic kidney disease (CKD).
NGAL was shown to be a sensitive biomarker for AKI in
dogs undergoing different types of surgeries and experimen-
tally in a canine model of gentamicin nephrotoxicity [22].
In an animal study, urinary NGAL levels that were mea-
sured by western blots were increased within 3 h after CP
treatment in an AKI study group [21]. In reply to multi-
farious kinds of damage, elicitation of multiple of this indi-
cator is known to elevate, and they may be distributed or
energetically discharged into the urine or blood flow [14].
Furthermore, it has been reported that NGAL synthesis is
also increased in cancer.
The aim of this study was to evaluate serum and urin-
ary biomarker including NGAL (sNGAL and uNGAL) in
canine with solid renal tumors who suffered from CP
after short and long-term chemotherapy.
Methods
Groups and cisplatin administration
Fifteen adult Iranian mixed-breed male dogs weighing
averagely 5 kg were evaluated in animal house in a pri-
vate clinic. The animal were assigned into two groups,
control group (n = 5) and test group (n = 10). Canine
number 11,12,13,14,15 were assigned as control animals
and dog number 1, 2, 3, 5, 6, 7,8,9,10 were as test groups
which received CP.
The animals were kept in cages separately and food and
water consumption were monitored twice daily, in morn-
ing and afternoon. Cisplatin (Mylan Pharmaceutical Co,
Greece) was administered intravenously at 1.2 mg/kg /day
for five sequential days. The injections were done via
cephalic vein gently in 1 min.
Serum and urine NGAL levels (ng/mL) was evaluated
at 0, 1, 5, 9, 13, 17, 21, 25 and 29 days after drug injec-
tion versus baseline in ten cases that have solid kidney
tumors with CKI also control group belonged to five
dog without CKI.
Clinical examinations
Physical and clinical examinations were performed on all
animals twice daily, in the morning (at approximately
4 h post-dosing on the days of compound administration
or between approximately 9 and 11 am) and in the after-
noon (at approximately 3 pm), for signs of toxicity in-
cluding decreased eating and/or drinking, changes in
behavior/motility (lethargy, ataxia, vocalizations, unre-
sponsiveness, and dehydration), morbidity, and mortality.
Individual body weights were recorded at study day-4
prior to test article administration. A final body weight
was recorded for each animal on the day of necropsy.
Food and water consumption were observed on all ani-
mals twice daily, in the morning and in the afternoon, by
visual inspection. Symptoms of drug toxicity including de-
creased food intake and water consumption, behavioral
changes, motility, mouth sores, nausea, and mortality were
examined. In this study, medical measures were under-
taken due to low number.
Specimen collection and measurement of biomarkers
Blood samples were collected via the jugular vein and
urine samples were collected via a urethral catheter, at 0
(before injection), 1, 5, 9, 13, 17, 21, 25 and 29 days after
administration CP. The animals had access to drinking
water and were fasted overnight prior to each scheduled
sample collection. Sera were separated from the clot by
centrifugation at 3000 rpm for 15 min using centrifuge.
Serum samples were separated into sterile plain tubes
and stored in the refrigerator for analyses. For the urine
NGAL analysis, urine specimens were transferred to
centrifuge tubes and centrifuged at a relative centrifugal
force ≥400 for 5 min. The supernatants were stored
at −70 °C until batch analysis. After thawing, the speci-
mens were mixed and centrifuged at 2,500 to 3,000 × g
for 10 min prior to use, to remove any particulate matter
and ensure consistency in the results.
Enzyme-linked immunosorbent assay (ELISA)
The serum and urine NGAL levels (sNGALand uNGAL)
were measured by sandwich ELISA and following the
procedure described in previous studies.
Briefly, the capture antibody (rabbit anti-NGAL poly-
clonal antibody), tested samples, and detection antibody
(mouse anti-NGAL polyclonal antibody) were diluted
1: 800, 1: 20, and 1: 3,000, respectively. After removal of
unbound antibody by washing with PBS, 5,000-fold di-
luted HRP-conjugated goat anti-mouse IgG antibody
was added to each well. After 1 h of incubation, the re-
sult was visualized using a tetramethylbenzidine sub-
strate kit. Each sample was tested in triplicate, and the









OD of the triplicates was averaged. Samples with an OD
value 3× > that of serum obtained from the normal con-
trol group were considered positive.
Statistical analysis
The software, SPSS Version 16.0 for Windows (SPSS
Inc., Chicago, IL, USA), was used for analysis. Differ-
ences were considered significant when P <0.05 using




In current study, we evaluated clinical signs due to CP‐
induced toxicity (Table 1). Our results revealed that clin-
ical changes occurred in the treatment group with CP.
Moreover, mortality was not seen in evaluated groups.
All canine in treatment group had shown symptoms of
toxicity of CP (Table 1).
Nephrotoxicity biomarker in kidney tissue
The following median values for sNGAL and uNGAL
were summarized in Table 2.
In CP-treated categories of both serum and urinary, the
results indicated the higher concentrations of serum,
sNGAL and uNGAL compared with control group (P =
0.024; P = 0.011, Table 2, Figs. 1 and 2). Indeed, our result
indicated that patients with CKI were associated with
higher levels of sNGAL and uNGAL compared with con-
trol group without CKI. Moreover, the highest level of
uNGAL was seen in comparison with sNGAL, after a high
dose (1.2 mg/kg) administration of CP. Short-term CP
chemotherapy (STC, 1 day) was compared to long-term
(LTC, 29 days) treatment using plasma and urine NGAL.
Patients with CKI linked to LTC had increased level of
S-NGAL and compared with control group without
CP-treated.
In addition, there were no statistically significant linear
correlations between baseline serum and urinary NGAL
levels in the CKI groups.
Discussion
NGAL is a 25-kDa protein which is known as a primary
indicator of acute and chronic renal trauma [14, 15]. It
has been reported that the expressions of NGAL are
rapidly up-regulated after renal injury in animal. It
is worth noting that research on animal model have
shown, which NGAL levels increase after ischemic kid-
ney injury or exposure to nephrotoxic drugs. Use of
NGAL as a marker in dogs with naturally occurring kid-
ney disease has only recently been explored in AKI [22].
In an animal study, urinary NGAL levels that were
measured by western blots were increased within 3 h
after CP treatment in an AKI study group [21]. In reply
to multifarious kinds of damage, elicitation of multiple
of this indicator is known to elevate, and they may be
distributed or energetically discharged into the urine or
blood flow [14]. Furthermore, NGAL synthesis is also in-
creased in cancer.
Recently, much attention has been given to NGAL in
veterinary nephrology but, there are no studies that
plasma and urinary NGAL as a biomarker of CP drug
induced ACRI in dogs with kidney cancer. This article
focuses on the biomarker NGAL and its potential utility
in the pathologic diagnosis, primary prognosis of de-
struction, and treatment of ACRI.
Table 1 Clinical signs after administration of cisplatin in during study period
Study Groups Case no Reducing drinking Reduce eating Changes in behavior and mobility Dehydration Nausea Mouth ulcers Mortality
Treatment 1 + + - - - - -
2 + + - + + - -
3 + + - - + + -
4 + + - - - - -
5 + + - + - + -
6 + + + + + - -
7 + + - + - - -
8 + + + + - - -
9 + + - + + - -
Control 10 + + + - - + -
11 - - - - - - -
12 - - - - - - -
13 - - - - - - -
14 - - - - - - -
15 - - - - - - -









Table 2 Median workup results of NGAL concentration (sNGA and uNGAL) after cisplatin chemotherapy in during treatment periods
Variables Day 0 Day 1 Day5 Day9 Day13 Day17 Day21 Day25 Day29 P*
sNGAL level in treated group 65.12 ± 6.73 68.23 ± 12.29 76.71 ± 18.56 96.64 ± 22.81 115.07 ± 21.01 134.20 ± 5.71 146 ± 6.21 150 ± 19.54 306.21 ± 25.47 P = 0.024
sNGAL level in Control 62 ± 10.74 61.53 ± 4.67 68.78 ± 8.23 73.32 ± 10..71 70.45 ± 10.58 81 ± 20.10 73.76 ± 10.32 78.37 ± 18.43 74.53 ± 16.43 P = 0.701
uNGAL level in treated group 47.64 ± 3.25 49.58 ± 314.35 90.83 ± 32.41 106.92 ± 37.54 127.41 ± 16.83 129.27 ± 27.86 163 ± 42.46 185.85 ± 20.12 386 ± 62.54 P = 0.011
uNGAL level in Control 49 ± 6.47 48.72 ± 22.61 46 ± 1.73 50 ± 9.16 53 ± 9.82 47.23 ± 15.46 40.54 ± 7.43 52.26 ± 12.33 51.34 ± 14.53 P = 0.612



















Our finding showed that the higher concentrations of
serum, sNGAL and uNGAL compared with control group
(P = 0.024; P = 0.011, Table 2). Indeed, CKI was associated
with higher levels of sNGAL and uNGAL compared with
exposed controls. Other preliminary investigations have
shown elevated serum and urine NGAL concentrations in
dogs with kidney diseases compared to controls [21].
The results of this study indicated that NGAL is a prom-
ising renal biomarker when serum and urine NGAL con-
centrations in CP treatment in CKI study group. However,
sNGAL can have from different origins and release is not
limited to the kidneys, concurrent diseases may contribute
to the increase in sNGAL and this might lead to predic-
tion of a poor prognosis.
It has been reported that chemotherapy with CP espe-
cially on the animal model, multifarious definitions of
acute and chronic renal injuries (ACRI) different settings
of ACRI [23–26].
It has been previously reported which NGAL levels
increase after ischemic kidney injury or exposure to
nephrotoxic drugs in animal model, For instance, after
CP-induced ACRI in mice, [13, 15] and also after acute
and chronic renal injuries in mice and rat models. It is
worth noting that detectable level of NGAL were observed
an hour after onset of injury, which precedes the urinary
appearance of beta-2 microglobulin and many other
markers of tubular injury [13]. It has been reported that
injury in proximal ducts in the renal cortex is mainly oc-
curred due to CP. In addition, the severity of acute renal
injury was extremely impressive in proximal tubules [26],
which it is in accordance with our finding. It is worth not-
ing that another study indicated that CP could cause ex-
tensive damage in renal cortex [27].
The present study indicated that uNGAL is a major
biomarker in comparison with sNGAL for the early risk
stratification of CKI after CP chemotherapy and is can
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Fig. 1 Median workup results of sNGAL after cisplatin chemotherapy in canine during treatment periods
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Fig. 2 Median workup results of uNGAL after cisplatin chemotherapy in during treatment periods









be as prognostic factor for the early detection of kidney in-
juries. The median uNGAL concentration at baseline was
significantly higher in dogs . Furthermore, at the several
studies have been exhibited that U-NGAL excretion pre-
dicted ACRI in patients with solid tumors such as renal
cancers receiving CP, which is in agreement with our
study. However, another study have been reported which
U-NGAL levels predicted ACRI in a multicenter cohort of
children with diarrhea-associated hemolytic uremic
syndrome [28–32]. In parallel, the highest level of
uNGAL was seen in comparison with sNGAL, after a
high dose administration of CP. This result is in agree-
ment with the finding previous report that suggested
the urinary NGAL as a marker of tubular damage de-
pends on these parameters [33].
Conclusions
Together taken, NGAL concentrations in urine and in
serum can be used clinically in dogs as biomarkers to
evaluate renal function. To the authors’ knowledge, this is
the first study that suggested that urinary and plasma
NGAL excretion after CP chemotherapy in dog with CKI.
Current study indicated that U-NGAL may be as ef-
fective marker to monitor renal injury in exposed CKI
patients to CP. Furthermore, a primary elevate in urinary
NGAL expulsion may help in identifying cases at danger
of CP-induced CKI that might profit from innovative
remedies to prevent CP nephrotoxicity. Further studies
are required to determine the true predictive and prog-
nostic value of NGAL for dogs with solid renal cancer
treated with CP.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OM, SHM, MD, and MFJ participated in the design of the study; MZ, and EY
participated in the data analyses and manuscript preparation, AM conducted
the biomarker examination and writing. All authors read and approved the
final manuscript.
Acknowledgements
The authors thank Dr. Fathi for his help with this manuscript.
Author details
1Doctor of Veterinary Medicine (DVM), Faculty of Veterinary Medicine, Islamic
Azad University, Karaj Branch, Karaj, Iran. 2Doctor of Veterinary Medicine
(DVM), Karaj, Iran. 3Under graduate of Veterinary Medicine, Faculty of
Veterinary Medicine, Islamic Azad University, Karaj Branch, Karaj, Iran. 4Center
for Chemical Biology, Indian Institute of Chemical Technology (iict), Tarnaka,
Hyderabad, India. 5Baqiyatallah University of Medical Sciences, Tehran, Iran.
6Cellular & Molecular Research Center, Kurdistan University of Medical
Sciences, Sanandaj, Iran.
Received: 1 June 2015 Accepted: 27 June 2015
References
1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs.
Nat Rev Drug Discov. 2005;4(4):307–20.
2. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460e4.
3. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer
chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93–130.
4. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene. 2003;22:7265–79.
5. Koag MC, Lai L, Lee S. Structural basis for the inefficient nucleotide
incorporation opposite cisplatin-DNA lesion by human DNA polymerase β.
J Biol Chem. 2014;289(45):31341–8.
6. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R. Urine NGAL
predicts severity of acute kidney injury after cardiac surgery: a prospective
study. Clin J Am Soc Nephrol. 2008;3(3):665–73.
7. McCullough PA, Shaw AD, Haase M, Bouchard J, Waikar SS. Diagnosis of
acute kidney injury using functional and injury biomarkers: workgroup
statements from the tenth Acute Dialysis Quality Initiative Consensus
Conference. Contrib Nephrol. 2013;182:13–29.
8. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms andmrenoprotective
strategies. Kidney Int. 2008;73(9):994–1007.
9. Negishi K, Noiri E, Doi K, Maeda-Mamiya R, Sugaya T. Monitoring of urinary
L-type fatty acid-binding protein predicts histological severity of acute
kidney injury. Am J Pathol. 2009;174:1154–9.
10. Noiri E, Doi K, Negishi K, Tanaka T, Hamasaki Y. Urinary fatty acid-binding
protein 1: an early predictive biomarker of kidney injury. Am J Physiol.
2009;296:F669–79.
11. Zager RA, Johnson AC, Becker K. Plasma and urinary heme oxygenase-1 in
AKI. J Am Soc Nephrol. 2012;23:1048–57.
12. Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z.
Postoperative biomarkers predict acute kidney injury and poor outcomes
after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748–57.
13. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis
and risk stratification of acute kidney injury:a systematic review. Kidney Int.
2008;73(9):1008–16.
14. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K. Identification of neutrophil
gelatinase-associated lipocalin as a novel early urinary biomarker for
ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–43.
15. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN. Association between
increases in urinary neutrophil gelatinase-associated lipocalin and acute renal
dysfunction after adult cardiac surgery. Anesthesiology. 2006;105(3):485–91.
16. Shavit L, Dolgoker I, Ivgi H, Assous M, Slotki I. Neutrophil gelatinase-
associated lipocalin as a predictor of complications and mortality in
patients undergoing non-cardiac major surgery. Kidney Blood Press Res.
2011;34(2):116–24.
17. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a
troponin-like biomarker for human acute kidney injury. Nephrology
(Carlton). 2010;15:419–28.
18. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M. Amelioration of
ischemic acute renal injury by neutrophil gelatinase-associated lipocalin.
J Am Soc Nephrol. 2004;15(12):3073–82.
19. Nickolas TL, O’Rourke MJ, Yang J. Sensitivity and specificity of a single
emergency department measurement of urinary neutrophil gelatinase-
associated lipocalin for diagnosing acute kidney injury. Ann Intern Med.
2008;148:810–9.
20. Tavasoly A, Gholami H, Rostami A, Anissian A, Touni SR, Khaleghian P, et al.
Clinico-histopathologic and outcome features of cutaneous infundibular
keratinizing acanthoma: a case report and literature review. World J Surg
Oncol. 2014;12:173.
21. Steinbach S, Weis J, Schweighauser A, Francey T, Neiger R. Plasma and urine
neutrophil gelatinase-associated lipocalin (NGAL) in dogs with acute kidney
injury or chronic kidney disease. J Vet Intern Med. 2014;28(2):264–9.
22. Hosohata K, Ando H, Fujimura A. Urinary vanin-1 as a novel biomarker for
early detection of drug-induced acute kidney injury. J Pharmacol Exp Ther.
2012;341(3):656–62.
23. Alavi-Shoushtari SM, Abedizadeh R, Khaki A, Mokarizadeh A, Dorostkar K. A
study on the effects of the estrous cycle on uterine fluid and blood serum
immunoglobulin G (IgG) content in the cow. Vet Res Forum. 2014;5(2):115–9.
24. Segev G, Palm C, Leroy B. Evaluation of neutrophil gelatinase-associated lipocalin
as a marker of kidney injury in dogs. J Vet Intern Med. 2013;27:1362–7.
25. Haase-Fielitz A, Bellomo R, Devarajan P. The predictive performance of
plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with
grade of acute kidney injury. Nephrol Dial Transplant. 2009;24:3349–54.
26. Shin YJ, Kim TH, Won AJ, Jung JY, Kwack SJ, Kacew S, et al. Age-related
differences in kidney injury biomarkers induced by cisplatin. Environ Toxicol
Pharmacol. 2014;37(3):1028–39.









27. Ali BH, Al-Moundhri M, Tageldin M, Al Husseini IS, Mansour MA. Ontogenic
aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol.
2008;46(11):3355–9.
28. Mokarizadeh A, Faryabi MR, Rezvanfar MA, Abdollahi M. A comprehensive
review of pesticides and the immune dysregulation: mechanisms, evidence
and consequences. Toxicol Mech Methods. 2015;11:1–21.
29. Supavekin S, Zhang W, Kucherlapati R. Differential gene expression
following early renal ischemia/reperfusion. Kidney Int. 2003;63:1714–24.
30. Yuen PS, Jo SK, Holly MK. Ischemic and nephrotoxic acute renal failure are
distinguished by their broad transcriptomic responses. Physiol Genomics.
2006;375:25–86.
31. Emberson JR, Haynes R, Dasgupta T, Mafham M, Landray MJ, Baigent C.
Cystatin C and risk of vascular and nonvascular mortality: a prospective
cohort study of older men. J Intern Med. 2010;268:145–54.
32. Liebetrau C, Gaede L, Doerr O, Blumenstein J, Rixe J, Teichert O. Neutrophil
gelatinase-associated lipocalin (NGAL) for the early detection of contrast-
induced nephropathy after percutaneous coronary intervention. Scand J
Clin Lab Invest. 2014;74(2):81–8.
33. Trachtman H, Christen E, Canaan A. Urinary neutrophil gelatinase associated
lipocalin in D1HUS: a novel marker of renal injury. Pediatr Nephrol.
2006;989:21–94.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Maghsoudi et al. Diagnostic Pathology  (2015) 10:98 Page 7 of 7
